表紙
市場調查報告書

長壽、抗老化治療的全球市場

Global Longevity and Anti-senescence Therapy Market

出版商 BCC Research 商品編碼 851711
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
長壽、抗老化治療的全球市場 Global Longevity and Anti-senescence Therapy Market
出版日期: 2019年05月23日內容資訊: 英文 102 Pages
簡介

全球長壽、抗老化治療市場預計將從2018年的3億2,980萬美元擴大到2023年的6億4,440萬美元,並以14.3%的年複合成長率 (CAGR) 擴大。

本報告提供全球長壽、抗老化治療市場調查,市場概要,市場趨勢的分析與預測,各市場區隔、各地區的分析與預測,及主要企業的簡介等系統性資訊。

第1章 簡介

第2章 摘要、亮點

第3章 市場概要

  • 簡介
  • 長壽、抗老化市場上所採用的藥物、設備、技術
  • 市場發展、主要的未來趨勢
  • 臨床實驗、產品銷售的預定
  • 規格、規定
  • 促進產業成長因素

第4章 全球長壽、抗老化市場:各治療法

  • 老化細胞消除藥療法
  • 遺傳基因療法
  • 免疫療法
  • 其他

第5章 全球長壽、抗老化市場:各用途

  • 長壽
  • 老化防止
  • 心血管疾病
  • 神經退化性疾病
  • 眼科疾病
  • 癌症

第6章 全球長壽、抗老化市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 長壽、抗老化市場上產業結構

  • 產業結構
  • 投資、資金分析

第8章 企業簡介

  • ACORDA THERAPEUTICS
  • AGEX THERAPEUTICS
  • ANTOXERENE
  • CALICO LIFE SCIENCES
  • CELGENE
  • CLEARA BIOTECH
  • COHBAR
  • HUMAN LONGEVITY INC.
  • INSILICO MEDICINE
  • OISIN BIOTECHNOLOGY
  • POWERVISION INC.
  • PRANA BIOTECHNOLOGY LTD.
  • PROTEOSTASIS THERAPEUTICS INC.
  • RECURSION PHARMACEUTICALS
  • RESTORBIO
  • SIERRA SCIENCES LLC
  • SENEX BIOTECHNOLOGY
  • SENOLYTIC THERAPEUTICS
  • SPOTLIGHT BIOSCIENCE
  • T.A. SCIENCES
  • UNITY BIOTECHNOLOGY
目錄
Product Code: BIO185A

Report Highlights:

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

The global senolytic drug therapy market of longevity and anti-senescence should grow from $99.4 million in 2018 to $196.9 million by 2023 with a CAGR of 14.6% during 2018-2023.

The global gene therapy market of longevity and anti-senescence should grow from $96.5 million in 2018 to $196.0 million by 2023 with a CAGR of 15.2% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

  • 71 data tables and 40 additional tables
  • An overview of the global longevity and anti-senescence therapy market
  • Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa
  • Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process
  • Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics
  • A look at the clinical trials and expected launch of anti-senescence products
  • Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market Overview

  • Introduction
  • Drugs, Devices and Technologies Used in the Longevity and Anti-senescence Market
  • Market Evolution and Key Future Trends
    • Timeline of Longevity and Anti-senescence
    • Key Future Trends
  • Clinical Trials and the Expected Launch of Anti-senescence Products
  • Standards and Regulations in the Market
    • United States
    • European Union
    • Japan
    • India
    • Brazil
  • Industry Growth Drivers
    • Increasing Geriatric Population Across the Globe
    • Surging Level of Disposable Income
    • Rising Awareness of Anti-Aging Products Among Generation Y and Later Generations
    • Increasing Advancements in Anti-senescence Technologies

Chapter 4: Global Longevity and Anti-senescence Market by Therapy

  • Senolytic Drug Therapy
  • Gene Therapy
  • Immunotherapy
  • Others

Chapter 5: Global Longevity and Anti-senescence Market by Application

  • Longevity
  • Senescence Inhibition
  • Cardiovascular Diseases
  • Neural Degenerative Diseases
  • Ophthalmology Disorders
  • Cancer

Chapter 6: Global Longevity and Anti-senescence Market by Region

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • France
    • Germany
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East and Africa

Chapter 7: Industry Structure in Longevity and Anti-senescence Market

  • Industry Structure
    • Suppliers
    • Research and Development
    • Manufacturing/Production
    • Distribution and Marketing
    • End Users
  • Investments and Funding Analysis

Chapter 8: Company Profiles

  • ACORDA THERAPEUTICS
  • AGEX THERAPEUTICS
  • ANTOXERENE
  • CALICO LIFE SCIENCES
  • CELGENE
  • CLEARA BIOTECH
  • COHBAR
  • HUMAN LONGEVITY INC.
  • INSILICO MEDICINE
  • OISIN BIOTECHNOLOGY
  • POWERVISION INC.
  • PRANA BIOTECHNOLOGY LTD.
  • PROTEOSTASIS THERAPEUTICS INC.
  • RECURSION PHARMACEUTICALS
  • RESTORBIO
  • SIERRA SCIENCES LLC
  • SENEX BIOTECHNOLOGY
  • SENOLYTIC THERAPEUTICS
  • SPOTLIGHT BIOSCIENCE
  • T.A. SCIENCES
  • UNITY BIOTECHNOLOGY

List of Tables

  • Summary Table: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 1: Various Approaches to Anti-aging Therapeutics
    • Table 2: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
    • Table 3: Drugs and Biologics Related to Aging Under Various Phases of Clinical Trials, as of January 2019
    • Table 4: Global Population Aged 60 Years and Older, by Region, 2015, 2030 and 2050
    • Table 5: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
    • Table 6: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
    • Table 7: Household Disposable Income Across Selected Countries, 2012-2018
    • Table 8: Lifetime UV Exposure in the United States
    • Table 9: Start-up Companies in Anti-Aging Solutions
    • Table 10: Global Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 11: Types of Senolytics Drugs
    • Table 12: Global Market for Senolytic Drug Therapy, by Region, Through 2023
    • Table 13: Population Aged 65 Years and Older, 2012-2017
    • Table 14: Global Market for Gene Therapy, by Region, Through 2023
    • Table 15: Leading Institutional Developers of Genomics Tools, 2017
    • Table 16: Global Market for Immunotherapy, by Region, Through 2023
    • Table 17: Global Market for Other Therapies, by Region, Through 2023
    • Table 18: Global Market for Longevity and Anti-senescence in Drug Discovery and Development, by Region, Through 2023
    • Table 19: Global Market for Longevity and Anti-senescence in Senescence Inhibition, by Region, Through 2023
    • Table 20: Global Market for Longevity and Anti-senescence in Cardiovascular Diseases, by Region, Through 2023
    • Table 21: Number of People with Dementia Worldwide, by Income Level, 2015-2050
    • Table 22: Investments in Alzheimer's Disease Treatment
    • Table 23: Global Market for Longevity and Anti-senescence in Neural Degenerative Diseases, by Region, Through 2023
    • Table 24: Global Market for Longevity and Anti-senescence in Ophthalmology Disorders, by Region, Through 2023
    • Table 25: Global Number of Adults with Diabetes, 2015 and 2040
    • Table 26: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
    • Table 27: Percentage Increment of Diabetes Across Regions, 2015-2040
    • Table 28: Global Market for Longevity and Anti-senescence in Cancer, by Region, Through 2023
    • Table 29: Global Cancer Prevalence, by Type, 2016
    • Table 30: Cancer Prevalence Across Regions, by Type, 2015-2016
    • Table 31: North American Number and Distribution of Persons Aged 60 Years or Older, 2017 and 2050
    • Table 32: Demographic Indicators Related to Population Aging in North America, by Country, 2017 and 2050
    • Table 33: North American Market for Longevity and Anti-senescence, by Country, Through 2023
    • Table 34: North American Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 35: North American Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 36: United States' Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 37: United States' Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 38: Canadian Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 39: Canadian Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 40: European Market for Longevity and Anti-senescence, by Country, Through 2023
    • Table 41: European Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 42: European Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 43: U.K. Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 44: UK Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 45: French Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 46: French Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 47: German Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 48: German Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 49: Spanish Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 50: Spanish Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 51: Rest of the European Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 52: Rest of the European Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 53: Asia-Pacific Market for Longevity and Anti-senescence, by Country, Through 2023
    • Table 54: Asia-Pacific Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 55: Asia-Pacific Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 56: Chinese Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 57: Chinese Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 58: Total Rural Income in India, 2015 and 2021
    • Table 59: Indian Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 60: Indian Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 61: Share of Population Aged 65 Years and Older in Japan, 2015 and 2050
    • Table 62: Japanese Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 63: Japanese Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 64: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
    • Table 65: Australian Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 66: Australian Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 67: Rest of APAC Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 68: Rest of APAC Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 69: RoW Market for Longevity and Anti-senescence, by Region, Through 2023
    • Table 70: RoW Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 71: RoW Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 72: Latin American Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 73: Latin American Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 74: Disposable Income in UAE, 2010 and 2017
    • Table 75: Middle Eastern and African Market for Longevity and Anti-senescence, by Therapy, Through 2023
    • Table 76: Middle Eastern and African Market for Longevity and Anti-senescence, by Application, Through 2023
    • Table 77: Global Suppliers to Longevity and Anti-senescence Market
    • Table 78: Some of the Notable Longevity and Anti-senescence Companies
    • Table 79: Investment Analysis: Longevity and Anti-senescence Therapy Market
    • Table 80: Product Portfolio: Acorda Therapeutics
    • Table 81: Product Portfolio: AgeX Therapeutics
    • Table 82: Recent Developments: AgeX Therapeutics, 2016-2018
    • Table 83: Product Portfolio: Antoxerene
    • Table 84: Recent Developments: Antoxerene, 2016-2018
    • Table 85: Recent Developments: Calico Life Sciences, 2016-2018
    • Table 86: Product Portfolio: Celgene
    • Table 87: Product Portfolio: Cleara Biotech
    • Table 88: Recent Developments: Cleara Biotech, 2016-2018
    • Table 89: Product Portfolio: CohBar
    • Table 90: Recent Developments: CohBar, 2016-2018
    • Table 91: Product Portfolio: Human Longevity Inc.
    • Table 92: Recent Developments: Human Longevity Inc., 2016-2018
    • Table 93: Product Portfolio: Insilico Medicine
    • Table 94: Recent Developments: Insilico Medicine, 2016-2018
    • Table 95: Product Portfolio: Oisin Biotechnology
    • Table 96: Product Portfolio: PowerVision Inc.
    • Table 97: Recent Developments: PowerVision Inc., 2016-2018
    • Table 98: Product Portfolio: Prana Biotechnology Ltd.
    • Table 99: Recent Developments: Prana Biotechnology Ltd., 2016-2018
    • Table 100: Product Portfolio: Proteostasis Therapeutics Inc.
    • Table 101: Product Portfolio: Recursion Pharmaceuticals
    • Table 102: Recent Developments: Recursion Pharmaceuticals, 2016-2018
    • Table 103: Product Portfolio: resTORbio
    • Table 104: Product Portfolio (Pipeline): Senex Biotechnology
    • Table 105: Product Portfolio: Senolytic Therapeutics
    • Table 106: Product Portfolio: Spotlight Bioscience
    • Table 107: Product Portfolio: T.A. Sciences
    • Table 108: Recent Developments: T.A. Sciences, 2016-2018
    • Table 109: Product Portfolio: Unity Biotechnology
    • Table 110: Recent Developments: Unity Biotechnology, 2017-2019

List of Figures

  • Summary Figure: Global Market for Longevity and Anti-senescence, by Therapy, 2017-2023
    • Figure 1: Increasing Global Life Expectancy (in Years) for Both Sexes, by Region, 2000-2016
    • Figure 2: Global Geriatric Population (Aged 65 Years and Older), 2014-2022
    • Figure 3: Percentage Distribution of Worldwide Population (Aged 65 Years and Older), by Region, 2016 and 2050
    • Figure 4: Household Disposable Income Across Selected Countries, 2012-2018
    • Figure 5: Population Aged 65 Years and Older, 2012-2017
    • Figure 6: Number of People with Dementia Worldwide, by Income Level, 2015-2050
    • Figure 7: Global Number of Adults with Diabetes, 2015 and 2040
    • Figure 8: Top 10 Countries with the Highest Prevalence of Diabetes, 2015
    • Figure 9: Percentage Distribution of Increasing Diabetes Cases, by Region, 2015-2040
    • Figure 10: Global Cancer Prevalence, by Type, 2016
    • Figure 11: Cancer Prevalence Across Regions, by Type, 2015-2016
    • Figure 12: Canadian Population Shares Distribution, by Province or Territory, 2018
    • Figure 13: Index of Mean and Median Equivalized Household Disposable Income in the U.K., 2015-2017
    • Figure 14: Geriatric Population in France, 2012 and 2017
    • Figure 15: Total Rural Income in India, 2015 and 2021
    • Figure 16: Share of Japanese Population Aged 65 Years and Older, 2015 and 2050
    • Figure 17: Share of Australian Population Aged 60 Years and Older, 2015 and 2050
    • Figure 18: Disposable Income in UAE, 2010 and 2017
    • Figure 19: Industry Structure and Process Flow: Longevity and Anti-senescence Industry
Back to Top